{"ticker": {"uuid": "65f0f55f-7674-45c0-bcf8-e9a0e2d7e4e7", "symbol": "MGNX", "name": "MacroGenics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "[144] MACROGENICS INC SEC Filing", "summary": "This article details a Form 144 SEC filing by MacroGenics Inc. for a proposed sale of securities under Rule 144. The filing indicates the sale of 17,000 common shares with an aggregate market value of $75,529, acquired on July 13, 2026, through a stock plan activity. The projecte", "url": "https://www.stocktitan.net/sec-filings/MGNX/144-macrogenics-inc-sec-filing-1e9342c1fb28.html", "source_name": "Stock Titan", "published_at": "2026-07-14T01:40:29", "published_display": "14 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MacroGenics (MGNX) Short Interest & Short Float | Updated Jul 2026", "summary": "MacroGenics (MGNX) saw a significant 38.33% increase in short interest as of June 30, 2026, with 6.63 million shares sold short, representing 12.07% of its public float. The short interest ratio stands at 3.5 days to cover. This data suggests growing bearish sentiment among inves", "url": "https://www.marketbeat.com/stocks/NASDAQ/MGNX/short-interest/", "source_name": "MarketBeat", "published_at": "2026-07-10T07:41:47", "published_display": "10 Jul 2026 07:41", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Macrogenics, Inc. Announces Resignation of Karen Ferrante from Director Role, Effective September 1, 2026", "summary": "Macrogenics, Inc. announced that Karen Ferrante, M.D. will resign from its board of directors, effective September 1, 2026. Dr. Ferrante's decision is for personal reasons and does not stem from any disagreement with the company's operations, policies, or practices. The announcem", "url": "https://www.marketscreener.com/news/macrogenics-inc-announces-resignation-of-karen-ferrante-from-director-role-effective-september-1-ce7f5edfdd88f422", "source_name": "www.marketscreener.com", "published_at": "2026-07-09T19:11:24", "published_display": "09 Jul 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics, Inc. 8-K SEC Filing July 2026: Company Details, Stock Info, and Key Regulatory Disclosures", "summary": "MacroGenics, Inc. (NASDAQ: MGNX) announced the resignation of Dr. Karen Ferrante from its board of directors, effective September 1, 2026, due to personal reasons. The company emphasized that her departure was amicable and not related to any disagreements, reassuring investors. T", "url": "https://www.minichart.com.sg/2026/07/09/macrogenics-inc-8-k-sec-filing-july-2026-company-details-stock-info-and-key-regulatory-disclosures/", "source_name": "Minichart", "published_at": "2026-07-09T01:10:34", "published_display": "09 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karen Ferrante to Resign from MacroGenics' Board Effective Sept 1, 2026", "summary": "MacroGenics (MGNX) announced that Karen Ferrante, M.D., will resign from its board of directors, effective September 1, 2026. The resignation is due to personal reasons and is not a result of any disagreement with the company. No information was disclosed regarding a replacement ", "url": "https://www.tradingview.com/news/tradingview:aab48c2a3b59e:0-karen-ferrante-to-resign-from-macrogenics-board-effective-sept-1-2026/", "source_name": "TradingView", "published_at": "2026-07-08T20:10:34", "published_display": "08 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Board member Karen Ferrante to leave MacroGenics (MGNX) board in September 2026", "summary": "MacroGenics, Inc. announced that board member Karen Ferrante, M.D. will resign from its board of directors effective September 1, 2026, due to personal reasons. She notified the board on July 1, 2026, and the company confirmed that her decision is not due to any disagreements reg", "url": "https://www.stocktitan.net/sec-filings/MGNX/8-k-macrogenics-inc-reports-material-event-6c41b11cd85b.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:10:34", "published_display": "08 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics Inc highlights its oncology pipeline as investors track future catalysts", "summary": "MacroGenics Inc, a US-based biotechnology company, is actively advancing its antibody-based cancer therapies, providing investors with exposure to the specialized immuno-oncology segment. The company focuses on developing monoclonal antibody and antibody-based product candidates ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/macrogenics-inc-highlights-its-oncology-pipeline-as-investors-track-future/69723704", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T13:10:12", "published_display": "08 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics (NASDAQ: MGNX) nets $110.7M and gain in CDMO sale", "summary": "MacroGenics, Inc. has completed the sale of its GMP drug substance manufacturing and CDMO operations to Bora Pharmaceuticals and Bora Biologics for $122.5 million. This divestiture resulted in net cash proceeds of $110.7 million and is expected to transform the company's pro form", "url": "https://www.stocktitan.net/sec-filings/MGNX/8-k-macrogenics-inc-reports-material-event-42e4d87c6c39.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:42:26", "published_display": "07 Jul 2026 20:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bora Pharmaceuticals Completes Acquisition of MacroGenics\u2019 Rockville Mfg. Ops", "summary": "Bora Pharmaceuticals has completed its acquisition of MacroGenics' GMP manufacturing operations, including its Rockville, MD biologics drug substance facility, for $122.5 million. This acquisition establishes Bora Biologics with a 20,000-liter U.S. biologics drug substance manufa", "url": "https://www.contractpharma.com/breaking-news/bora-pharmaceuticals-completes-acquisition-of-macrogenics-rockville-mfg-ops/", "source_name": "Contract Pharma", "published_at": "2026-07-07T18:42:26", "published_display": "07 Jul 2026 18:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals", "summary": "MacroGenics, a clinical-stage biopharmaceutical company, has completed the sale of its GMP drug substance manufacturing operations to Bora Pharmaceuticals for $122.5 million. As part of the deal, Bora Pharmaceuticals has acquired MacroGenics' manufacturing site in Rockville, Mary", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MGNX-Q/pressreleases/3099278/macrogenics-completes-sale-of-gmp-manufacturing-operations-to-bora-pharmaceuticals/", "source_name": "The Globe and Mail", "published_at": "2026-07-03T04:39:08", "published_display": "03 Jul 2026 04:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bora Pharmaceuticals Completes Acquisition of MacroGenics\u2019 Rockville Manufacturing Operations", "summary": "Bora Pharmaceuticals has completed its acquisition of MacroGenics' GMP manufacturing operations, including a biologics drug substance facility in Rockville, Maryland, and a warehousing center, for $122.5 million. This acquisition establishes a 20,000-liter US biologics drug subst", "url": "https://www.media-outreach.com/news/taiwan/2026/07/02/474049/bora-pharmaceuticals-completes-acquisition-of-macrogenics-rockville-manufacturing-operations/", "source_name": "Media OutReach Newswire", "published_at": "2026-07-03T04:09:41", "published_display": "03 Jul 2026 04:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics Closes Sale of Manufacturing Operations to Bora Pharmaceuticals", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/macrogenics-closes-sale-manufacturing-operations-160645685.html", "source_name": "MT Newswires", "published_at": "2026-07-02T16:06:45+00:00", "published_display": "02 Jul 2026 16:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bora Pharmaceuticals Completes Acquisition of MacroGenics' Rockville Manufacturing Operations", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bora-pharmaceuticals-completes-acquisition-macrogenics-150000164.html", "source_name": "ACCESS Newswire", "published_at": "2026-07-02T15:00:00+00:00", "published_display": "02 Jul 2026 15:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics completes sale of manufacturing operations to Bora", "summary": "MacroGenics Inc. has completed the sale of its drug substance manufacturing operations to Bora Pharmaceuticals Co., Ltd. for $122.5 million. This transaction includes the transfer of MacroGenics' Rockville and Frederick facilities, along with approximately 140 employees. The deal", "url": "https://www.investing.com/news/company-news/macrogenics-completes-sale-of-manufacturing-operations-to-bora-93CH-4773284", "source_name": "Investing.com", "published_at": "2026-07-02T13:39:15", "published_display": "02 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics sells its drug-making operations to Bora for $122.5M", "summary": "MacroGenics (NASDAQ: MGNX) completed the sale of its GMP drug substance manufacturing operations to Bora Pharmaceuticals for $122.5 million. The deal includes the transfer of MacroGenics' manufacturing site in Rockville, Maryland, and its Frederick warehouse, along with approxima", "url": "https://www.stocktitan.net/news/MGNX/macro-genics-completes-sale-of-gmp-manufacturing-operations-to-bora-d9n39n89v1ll.html", "source_name": "Stock Titan", "published_at": "2026-07-02T13:39:15", "published_display": "02 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOX0pRdktpemN1R2F1Y0hDT045WTRIc0hkWTYzeDdSRTR2cnB2aUFrZjJTZW9hV0lUUTc3aE8tbUpGVUlTTGtLcDI1dU5iM3JEWDM1dmQ3U0NKWXZ4SHdEdmNIU2hfa2NwWFBFQ19fdklNOGxueTdfenBvbHpEcXBZVG1DbGg0WFh1VmRpU1FkelhQN2I4RzdIbGFJWVFVOG9iajg5Rg?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 2500 Growth Benchmark", "summary": "MacroGenics, Inc. (NasdaqGS: MGNX) has been added to the Russell 2500 Growth Benchmark as of June 29, 2026. This inclusion reflects the company's growth characteristics and follows several other Russell index additions on the same date, including the Russell Small Cap Comp Growth", "url": "https://www.marketscreener.com/news/macrogenics-inc-nasdaqgs-mgnx-added-to-russell-2500-growth-benchmark-ce7f5fdfda81f125", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:11:47", "published_display": "29 Jun 2026 19:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of MacroGenics, Inc. \u2013 NASDAQ:MGNX", "summary": "This article focuses on the enterprise value to revenue forward metric for MacroGenics, Inc. (NASDAQ: MGNX). It indicates that the information is provided by TradingView's financial data section. The content primarily serves as a placeholder or a brief mention within a larger fin", "url": "https://www.tradingview.com/symbols/NASDAQ-MGNX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T01:12:17", "published_display": "29 Jun 2026 01:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of MacroGenics, Inc. \u2013 NASDAQ:MGNX", "summary": "This article briefly mentions the price to sales forward metric for MacroGenics, Inc. (NASDAQ: MGNX). It appears to be a stub or a section focused solely on this financial data point within a larger platform like TradingView, lacking substantial textual content or analysis. The m", "url": "https://www.tradingview.com/symbols/NASDAQ-MGNX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T21:39:35", "published_display": "28 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of MacroGenics, Inc. \u2013 NASDAQ:MGNX", "summary": "This article displays financial information for MacroGenics, Inc. (NASDAQ: MGNX) focusing on its price to earnings forward ratio. The content is primarily a data placeholder from TradingView, indicating where specific financial metrics would be presented.", "url": "https://www.tradingview.com/symbols/NASDAQ-MGNX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T15:09:14", "published_display": "28 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of MacroGenics, Inc. \u2013 BOATS:MGNX", "summary": "This article focuses on the enterprise value to revenue forward for MacroGenics, Inc. (MGNX). It provides financial data and an overview of the company's performance within the Health Technology and Pharmaceuticals sector. The content, available through TradingView and supported ", "url": "https://www.tradingview.com/symbols/BOATS-MGNX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:40:46", "published_display": "28 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of MacroGenics, Inc. \u2013 BOATS:MGNX", "summary": "This article provides financial data for MacroGenics, Inc. (MGNX), specifically focusing on its \"Price to book forward\" metric. The content highlights the stock's performance within the Health Technology and Pharmaceuticals sector, presenting an overview from the Blue Ocean Alter", "url": "https://www.tradingview.com/symbols/BOATS-MGNX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T16:39:35", "published_display": "27 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MGNX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for MacroGenics, Inc. (MGNX) stock, including analyst price targets, past performance, and future estimates. It highlights that analysts have a max price estimate of $9.00 and a min estimate of $4.00, with the stock having seen significant growth ", "url": "https://www.tradingview.com/symbols/NASDAQ-MGNX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T08:40:06", "published_display": "26 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics, Inc. Actuals & Estimates (NASDAQ:MGNX)", "summary": "This article provides an overview of MacroGenics, Inc. (NASDAQ:MGNX) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts, financial estimates, and key financial metrics like earnings, revenue, and EBITDA. The report ", "url": "https://www.tradingview.com/symbols/NASDAQ-MGNX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:39:48", "published_display": "26 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "M55 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for MacroGenics, Inc. (M55) stock, based on analyst opinions, with a max estimate of 7.29 CHF and a min estimate of 3.24 CHF. It also includes key financial data such as market capitalization, recent earnings, revenue, net income,", "url": "https://www.tradingview.com/symbols/BX-M55/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T00:39:48", "published_display": "26 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics: 'Hold' Potential Best-In-Class B7-H3 ADC And TZIELD Payment (NASDAQ:MGNX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQTHVpME13UXZoVnpXQ25KVC1mcXhNWm9tZ21RMHR1Q2tjNkd3c1ZxS3l3b05weDNFUlhBN3FtLWx4T280ZWpMT2UxeTVybDVKYzFmZTRpb3V0czJzblJpM0tEcEtuSmRtT0Q4N1g3X0p1bjUwTFhQckx1eVZ6Q0R0MnpYR0g5ZGttSmZacVNwOVZkaGZEMi11SW4wakpxaUIzTHVhOW5PeXNoQ1JyZm1j?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics To Receive $24.5 Million Milestone From Sanofi For TZIELD Approval", "summary": "MacroGenics will receive a $24.5 million regulatory milestone payment from Sanofi after the FDA granted accelerated approval for TZIELD. This approval expands TZIELD's use for delaying the decline in endogenous insulin production in children aged eight to 17 years with recently d", "url": "https://pulse2.com/macrogenics-to-receive-24-5-million-milestone-from-sanofi-for-tzield-approval/", "source_name": "Pulse 2.0", "published_at": "2026-06-24T02:40:53", "published_display": "24 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics to Receive $24.5 Million in Regulatory Milestone Payment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/macrogenics-receive-24-5-million-205502219.html", "source_name": "MT Newswires", "published_at": "2026-06-22T20:55:02+00:00", "published_display": "22 Jun 2026 20:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD\u00ae Approval", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/macrogenics-receive-milestone-payment-sanofi-204300752.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T20:43:00+00:00", "published_display": "22 Jun 2026 20:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics stock rises on $24.5M Sanofi milestone payment", "summary": "MacroGenics Inc. (NASDAQ:MGNX) saw its shares increase after-hours due to a $24.5 million milestone payment from Sanofi. This payment followed FDA accelerated approval for TZIELD (teplizumab-mzwv) which expands its use for delaying the decline in insulin production in children wi", "url": "https://www.investing.com/news/stock-market-news/macrogenics-stock-rises-on-245m-sanofi-milestone-payment-93CH-4753948", "source_name": "Investing.com", "published_at": "2026-06-22T21:10:06", "published_display": "22 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sanofi\u2019s TZIELD approval triggers $24.5M payment to MacroGenics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOQzhzVzBwa1p0eTlGOGx3SnBYd2xtS1g2eGhtVVRxQ3VPdlVhWlIybTd6WEdVNmZLZUl3QVdYOE9pRnR2OXNqd09pVXVTd29fMHJaLVJKcm9CSzVCWndVdkJMOVo0a2VIbkxyU19uTWh6QXJzR2hzaGdTQ2YyeDU3S2lHVUtUZlhveU1ldzVpcm45SUczUERTZW56S0ZoalJxNzltWDVrd01ZV2hkQUEtT1F2ZWN1VmYzUk9Z?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The MacroGenics (MGNX) Story Is Shifting With ADC Pipeline Bets And 2026 Data Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOVTFnMmNmengxWHJpSU9VSl8tbm10RjMtUkM1c3NaakFDRkxwM0g1Nlc5elJ1TnlESUluUnBJOWxDcnVMU21hRVctN2pJaFYwbVU3MmUtV3BqTzc5cXN2RVo3dEZmOUEtYUFVdHZIcWg5UEdHLUFmYkZtWjRtQ1VrclJlR3VBUXU0M3drbUtiNzVwUGdUcGRFZV8wdWJBaXBWRzBsd05XNA?oc=5", "source_name": "Market source", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The MacroGenics (MGNX) Story Is Shifting With ADC Hopes And Execution Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQQ2Y0bFBLRzFNRjRHTVUtX0h6WWZ1SmVpZVVKZzB4TUkzZFctNHZScmJVbGt3Mm9kQ1owZmVDbTZQTnhHQjhxeEhuOEpyZFpDZkNZcEdFczNjdzEwZVFBSThua1VpTnVvSW9vajJHb1lmd0daSkdqSWJiTC1vMUs0TUlELTRLUnFaUkZuNjhHNnJibXFySHNVbGhwWWhTVXJ5WVE?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MacroGenics (MGNX) Quarterly Loss Of US$36.8 Million Tests Bullish Path To Profitability", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MacroGenics stock (US5562221046): $122.5M manufacturing sale to Bora marks strategic pivot", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOZk5zZ0Jid0VHVDdiVjJSRWc2Z090SHB3Rmt3Z3BtdG1hOHREdlJ4MEFGVFE4cEY1dlFtcHg5aTU5ZTA0RXloSmJLYk1QSXVfY2xrUDZ6OE1SbHJmLUNoWXlJQ3dtM1gyM1hLQ0YyeGhqanpTcm5VejJMekZNVHI2ZlJpaWwzRlg2NVNpdEZVazlGOVRTRXprNFhDR0gyZ3Nucy1wVDZrLXo1cTR3ekNLX2pkWV91YU8waU1VYTBaMWpub3FVTHo2LQ?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GMP Manufacturing Sale Gives MacroGenics Additional Non-Dilutive Capital for Pipeline Development (MGNX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOOUczZGx6SEtwRDBVSkRBLXdUVlBwTHdMWEJ5dE9TbW1pYm5qY1YyZEo3akNIcFdtQlF2bXNRTlk2el91c213dUZtMHBDSGJWZGhJcjlQZjRBMHlYV04xd3k4RGh1OG5ISGJob0JfRDBKcENZVnZWdDRPTWc2MGxNS1VJVXVIV3h6bmJZMkVMQWJ6dFNNOUtMTF92ZEhieGc3eXM2dDljamxPS3NtWkE?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics sells manufacturing operations to Bora for $122.5M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOZVJWVi1nUThnX0oxbXA1bHpNc2JqcDRCcEswLTRxcElOcUd2NDV2ZWZKbU1oMGlhZmk0c1l2MFlhRVFkMHRJRHZzMVZjSXFsaWpzbHdUR2dTOGhQYm5qMFVQUmpoOGV2cE1UVFZkS05SdXQ1MlZZZ3dyYXVGdTY1RmJQaFZkcDNfQnFfclFKUFIxR2w5LUZZdWI0X0hYT1Z0azctc1BBWlh6TFN3LUpSUkc2bG5FRUZf?oc=5", "source_name": "Investing.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics Sells GMP Manufacturing Operations to Bora Pharmaceuticals for $122.5 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNRkZ1ZHk3Y1pQUnNwdGFzTGxjOHBhRHFweElWNUhkVXdlQzJ0enk4VENHRUR4RHItc3NSc1dEX2xFUmpfNmNRd1p5azNhNW5DSmZaMGQyUnJ6NDVZQ2ktcnlRM3Joa0xYbTMyaXc3eW1YUkt0WDhyMjNrbmQwN2tYUWtKV082WWUtNFQxOFZlakVwUXhWVEtxUkpDVEh4TFFTdEVJaEpBLXFNN2dYd1ktV0JEbkhMRHRDVVM1VUpDY2ttQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Will MacroGenics (MGNX) Report Negative Q1 Earnings? What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNam5yUU4yaWE5M0tkLVZ3R2JXWGFQU3BHVGtyNUhieHRUNlBncmVDVVJsTlNvdlNRazF0ZG9uV1ZOWGFGZUhWMkpXMkJNTXBtSXl5MEppVk9FZWI3QkM1N19lTFI3aldlQ3d4V29BRktDQjM4ZlB3aGZzMHVrSW11eDRCU3lHTGRnZkVzRnA1NmRQUzNPRFgza3lhUmRBamgxVHc?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ\u00ae Royalty Purchase Agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPQThSNUV6eTlzdVEycnZGcHUwVzVXVlVMOWQwaW4ySVVsQW9TX0QwbzNNOUtNNVFtRVNCZ3l2MzFhV01iWGdHS1FURENsdzFyZzEtZllhN0syWDgzaGYyeXV0SVA4dllrMjUxcTl4WmJpRGVOTGExTzlBY3E1cDRzQ3hTOFBNNEF0WngxTjZYd0NfUUZRZi1WcXpVQ3FEd0VOaXZxT3lYdGp3SlpHSHVaMzhXaw?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "B. Riley Sees Upside in MacroGenics, Inc. (MGNX) Following Gilead-Driven Sector Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQTEVVU1R5Mmg0aFZhV1dDVDVkbVlKWWs2RXRlR3JpbU03elV4T1hSeFFHOWN5ejJYU1VDdTVoZFVrVDc4WERyVlNWYW5kU3hENkZTLVZJT2RMWjNCZklEd2p2NUZ2blMzazBQWW4tNmRkWS0zRXppY1dVeFB3eHdUNU1kSkpRQ2R3WlUwc1dMMXFzT3lmU05qMWFCT3NIV2lCV1E?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble (MGNX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPTFRpeEJfWVFNU0lKODBMZ3FhYnA4OWxfZmJ0bEZNWmhNLUZOVlhEdV9GQTF4QlE4OFJIUk9YT0tpWm5KUXZQY0FpZzdfU0FGaG9nbFJ0VmNCbURkTVdnc1FRUE1zcGRjc2VFUWhhdnFpdWVmZ19DN3lxRzJnWmVaLXhfeFQ2MmxTbF9ZQmRkZEZKZmZ1NTV2anNRd055cU9PZFhaVHBScV9lTGdyR2xDc0NBb3JLdTlo?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics gains removal of FDA partial hold on lead program", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxOd2JRZkZzSFpDbU14TkVPODhCdjREV3NOUUpJR2c5MjVoWG9UbTYzWDBoM0txSVF3V25QM0VUWGRLMHVDR01nNXN0YUVmQzFYb2JWWFBNM2FoMjAxTUViMnNMbVZuY0ZWSXY5T2FKckt5Q05VcUtqVGNyYkt4dlp3RHZKTzl5OVE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues Despite A 26% Share Price Rise", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics, Inc. (NASDAQ:MGNX) is largely controlled by institutional shareholders who own 71% of the company", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQdThkeGVSMVgzTGltODNueFdGUXcyVUdVNFVIUHZhS1ZqcEJEbjJxOUxxaUVGWGN4RUlCYkZEemFmdjZSTFkzbVlaUnRlUUhxOXdLNW5wcnpnazd6QkR1Wno1aXhmUzEwUFgxelJvcUEtVGR3aWduTVZwclJpcVZJaUF5cVpRZHlf?oc=5", "source_name": "Market source", "published_at": "2025-07-11T07:00:00+00:00", "published_display": "11 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Macrogenics (MGNX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFAwQWs1bmVKRVBhVnJGOGloV3dnejJwZUtsTkNmQmNNVWEzMUpnc19KeTkzYzlnaURnZ3k3NmtOLUF3Z1VINHpnZWFZMlFIYUxwdm5N?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:24:13+00:00", "published_display": "25 Apr 2025 00:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "[144] MACROGENICS INC SEC Filing", "summary": "This article details a Form 144 SEC filing by MacroGenics Inc. for a proposed sale of securities under Rule 144. The filing indicates the sale of 17,000 common shares with an aggregate market value of $75,529, acquired on July 13, 2026, through a stock plan activity. The projecte", "url": "https://www.stocktitan.net/sec-filings/MGNX/144-macrogenics-inc-sec-filing-1e9342c1fb28.html", "source_name": "Stock Titan", "published_at": "2026-07-14T01:40:29", "published_display": "14 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics (MGNX) Short Interest & Short Float | Updated Jul 2026", "summary": "MacroGenics (MGNX) saw a significant 38.33% increase in short interest as of June 30, 2026, with 6.63 million shares sold short, representing 12.07% of its public float. The short interest ratio stands at 3.5 days to cover. This data suggests growing bearish sentiment among inves", "url": "https://www.marketbeat.com/stocks/NASDAQ/MGNX/short-interest/", "source_name": "MarketBeat", "published_at": "2026-07-10T07:41:47", "published_display": "10 Jul 2026 07:41", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Macrogenics, Inc. Announces Resignation of Karen Ferrante from Director Role, Effective September 1, 2026", "summary": "Macrogenics, Inc. announced that Karen Ferrante, M.D. will resign from its board of directors, effective September 1, 2026. Dr. Ferrante's decision is for personal reasons and does not stem from any disagreement with the company's operations, policies, or practices. The announcem", "url": "https://www.marketscreener.com/news/macrogenics-inc-announces-resignation-of-karen-ferrante-from-director-role-effective-september-1-ce7f5edfdd88f422", "source_name": "www.marketscreener.com", "published_at": "2026-07-09T19:11:24", "published_display": "09 Jul 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics, Inc. 8-K SEC Filing July 2026: Company Details, Stock Info, and Key Regulatory Disclosures", "summary": "MacroGenics, Inc. (NASDAQ: MGNX) announced the resignation of Dr. Karen Ferrante from its board of directors, effective September 1, 2026, due to personal reasons. The company emphasized that her departure was amicable and not related to any disagreements, reassuring investors. T", "url": "https://www.minichart.com.sg/2026/07/09/macrogenics-inc-8-k-sec-filing-july-2026-company-details-stock-info-and-key-regulatory-disclosures/", "source_name": "Minichart", "published_at": "2026-07-09T01:10:34", "published_display": "09 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Karen Ferrante to Resign from MacroGenics' Board Effective Sept 1, 2026", "summary": "MacroGenics (MGNX) announced that Karen Ferrante, M.D., will resign from its board of directors, effective September 1, 2026. The resignation is due to personal reasons and is not a result of any disagreement with the company. No information was disclosed regarding a replacement ", "url": "https://www.tradingview.com/news/tradingview:aab48c2a3b59e:0-karen-ferrante-to-resign-from-macrogenics-board-effective-sept-1-2026/", "source_name": "TradingView", "published_at": "2026-07-08T20:10:34", "published_display": "08 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Board member Karen Ferrante to leave MacroGenics (MGNX) board in September 2026", "summary": "MacroGenics, Inc. announced that board member Karen Ferrante, M.D. will resign from its board of directors effective September 1, 2026, due to personal reasons. She notified the board on July 1, 2026, and the company confirmed that her decision is not due to any disagreements reg", "url": "https://www.stocktitan.net/sec-filings/MGNX/8-k-macrogenics-inc-reports-material-event-6c41b11cd85b.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:10:34", "published_display": "08 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics Inc highlights its oncology pipeline as investors track future catalysts", "summary": "MacroGenics Inc, a US-based biotechnology company, is actively advancing its antibody-based cancer therapies, providing investors with exposure to the specialized immuno-oncology segment. The company focuses on developing monoclonal antibody and antibody-based product candidates ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/macrogenics-inc-highlights-its-oncology-pipeline-as-investors-track-future/69723704", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T13:10:12", "published_display": "08 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics (NASDAQ: MGNX) nets $110.7M and gain in CDMO sale", "summary": "MacroGenics, Inc. has completed the sale of its GMP drug substance manufacturing and CDMO operations to Bora Pharmaceuticals and Bora Biologics for $122.5 million. This divestiture resulted in net cash proceeds of $110.7 million and is expected to transform the company's pro form", "url": "https://www.stocktitan.net/sec-filings/MGNX/8-k-macrogenics-inc-reports-material-event-42e4d87c6c39.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:42:26", "published_display": "07 Jul 2026 20:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bora Pharmaceuticals Completes Acquisition of MacroGenics\u2019 Rockville Mfg. Ops", "summary": "Bora Pharmaceuticals has completed its acquisition of MacroGenics' GMP manufacturing operations, including its Rockville, MD biologics drug substance facility, for $122.5 million. This acquisition establishes Bora Biologics with a 20,000-liter U.S. biologics drug substance manufa", "url": "https://www.contractpharma.com/breaking-news/bora-pharmaceuticals-completes-acquisition-of-macrogenics-rockville-mfg-ops/", "source_name": "Contract Pharma", "published_at": "2026-07-07T18:42:26", "published_display": "07 Jul 2026 18:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals", "summary": "MacroGenics, a clinical-stage biopharmaceutical company, has completed the sale of its GMP drug substance manufacturing operations to Bora Pharmaceuticals for $122.5 million. As part of the deal, Bora Pharmaceuticals has acquired MacroGenics' manufacturing site in Rockville, Mary", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MGNX-Q/pressreleases/3099278/macrogenics-completes-sale-of-gmp-manufacturing-operations-to-bora-pharmaceuticals/", "source_name": "The Globe and Mail", "published_at": "2026-07-03T04:39:08", "published_display": "03 Jul 2026 04:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bora Pharmaceuticals Completes Acquisition of MacroGenics\u2019 Rockville Manufacturing Operations", "summary": "Bora Pharmaceuticals has completed its acquisition of MacroGenics' GMP manufacturing operations, including a biologics drug substance facility in Rockville, Maryland, and a warehousing center, for $122.5 million. This acquisition establishes a 20,000-liter US biologics drug subst", "url": "https://www.media-outreach.com/news/taiwan/2026/07/02/474049/bora-pharmaceuticals-completes-acquisition-of-macrogenics-rockville-manufacturing-operations/", "source_name": "Media OutReach Newswire", "published_at": "2026-07-03T04:09:41", "published_display": "03 Jul 2026 04:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics Closes Sale of Manufacturing Operations to Bora Pharmaceuticals", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/macrogenics-closes-sale-manufacturing-operations-160645685.html", "source_name": "MT Newswires", "published_at": "2026-07-02T16:06:45+00:00", "published_display": "02 Jul 2026 16:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bora Pharmaceuticals Completes Acquisition of MacroGenics' Rockville Manufacturing Operations", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bora-pharmaceuticals-completes-acquisition-macrogenics-150000164.html", "source_name": "ACCESS Newswire", "published_at": "2026-07-02T15:00:00+00:00", "published_display": "02 Jul 2026 15:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics completes sale of manufacturing operations to Bora", "summary": "MacroGenics Inc. has completed the sale of its drug substance manufacturing operations to Bora Pharmaceuticals Co., Ltd. for $122.5 million. This transaction includes the transfer of MacroGenics' Rockville and Frederick facilities, along with approximately 140 employees. The deal", "url": "https://www.investing.com/news/company-news/macrogenics-completes-sale-of-manufacturing-operations-to-bora-93CH-4773284", "source_name": "Investing.com", "published_at": "2026-07-02T13:39:15", "published_display": "02 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics sells its drug-making operations to Bora for $122.5M", "summary": "MacroGenics (NASDAQ: MGNX) completed the sale of its GMP drug substance manufacturing operations to Bora Pharmaceuticals for $122.5 million. The deal includes the transfer of MacroGenics' manufacturing site in Rockville, Maryland, and its Frederick warehouse, along with approxima", "url": "https://www.stocktitan.net/news/MGNX/macro-genics-completes-sale-of-gmp-manufacturing-operations-to-bora-d9n39n89v1ll.html", "source_name": "Stock Titan", "published_at": "2026-07-02T13:39:15", "published_display": "02 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOX0pRdktpemN1R2F1Y0hDT045WTRIc0hkWTYzeDdSRTR2cnB2aUFrZjJTZW9hV0lUUTc3aE8tbUpGVUlTTGtLcDI1dU5iM3JEWDM1dmQ3U0NKWXZ4SHdEdmNIU2hfa2NwWFBFQ19fdklNOGxueTdfenBvbHpEcXBZVG1DbGg0WFh1VmRpU1FkelhQN2I4RzdIbGFJWVFVOG9iajg5Rg?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 2500 Growth Benchmark", "summary": "MacroGenics, Inc. (NasdaqGS: MGNX) has been added to the Russell 2500 Growth Benchmark as of June 29, 2026. This inclusion reflects the company's growth characteristics and follows several other Russell index additions on the same date, including the Russell Small Cap Comp Growth", "url": "https://www.marketscreener.com/news/macrogenics-inc-nasdaqgs-mgnx-added-to-russell-2500-growth-benchmark-ce7f5fdfda81f125", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:11:47", "published_display": "29 Jun 2026 19:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of MacroGenics, Inc. \u2013 NASDAQ:MGNX", "summary": "This article focuses on the enterprise value to revenue forward metric for MacroGenics, Inc. (NASDAQ: MGNX). It indicates that the information is provided by TradingView's financial data section. The content primarily serves as a placeholder or a brief mention within a larger fin", "url": "https://www.tradingview.com/symbols/NASDAQ-MGNX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T01:12:17", "published_display": "29 Jun 2026 01:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of MacroGenics, Inc. \u2013 NASDAQ:MGNX", "summary": "This article briefly mentions the price to sales forward metric for MacroGenics, Inc. (NASDAQ: MGNX). It appears to be a stub or a section focused solely on this financial data point within a larger platform like TradingView, lacking substantial textual content or analysis. The m", "url": "https://www.tradingview.com/symbols/NASDAQ-MGNX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T21:39:35", "published_display": "28 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of MacroGenics, Inc. \u2013 NASDAQ:MGNX", "summary": "This article displays financial information for MacroGenics, Inc. (NASDAQ: MGNX) focusing on its price to earnings forward ratio. The content is primarily a data placeholder from TradingView, indicating where specific financial metrics would be presented.", "url": "https://www.tradingview.com/symbols/NASDAQ-MGNX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T15:09:14", "published_display": "28 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of MacroGenics, Inc. \u2013 BOATS:MGNX", "summary": "This article focuses on the enterprise value to revenue forward for MacroGenics, Inc. (MGNX). It provides financial data and an overview of the company's performance within the Health Technology and Pharmaceuticals sector. The content, available through TradingView and supported ", "url": "https://www.tradingview.com/symbols/BOATS-MGNX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:40:46", "published_display": "28 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of MacroGenics, Inc. \u2013 BOATS:MGNX", "summary": "This article provides financial data for MacroGenics, Inc. (MGNX), specifically focusing on its \"Price to book forward\" metric. The content highlights the stock's performance within the Health Technology and Pharmaceuticals sector, presenting an overview from the Blue Ocean Alter", "url": "https://www.tradingview.com/symbols/BOATS-MGNX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T16:39:35", "published_display": "27 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MGNX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for MacroGenics, Inc. (MGNX) stock, including analyst price targets, past performance, and future estimates. It highlights that analysts have a max price estimate of $9.00 and a min estimate of $4.00, with the stock having seen significant growth ", "url": "https://www.tradingview.com/symbols/NASDAQ-MGNX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T08:40:06", "published_display": "26 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics, Inc. Actuals & Estimates (NASDAQ:MGNX)", "summary": "This article provides an overview of MacroGenics, Inc. (NASDAQ:MGNX) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts, financial estimates, and key financial metrics like earnings, revenue, and EBITDA. The report ", "url": "https://www.tradingview.com/symbols/NASDAQ-MGNX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:39:48", "published_display": "26 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "M55 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for MacroGenics, Inc. (M55) stock, based on analyst opinions, with a max estimate of 7.29 CHF and a min estimate of 3.24 CHF. It also includes key financial data such as market capitalization, recent earnings, revenue, net income,", "url": "https://www.tradingview.com/symbols/BX-M55/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T00:39:48", "published_display": "26 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics: 'Hold' Potential Best-In-Class B7-H3 ADC And TZIELD Payment (NASDAQ:MGNX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQTHVpME13UXZoVnpXQ25KVC1mcXhNWm9tZ21RMHR1Q2tjNkd3c1ZxS3l3b05weDNFUlhBN3FtLWx4T280ZWpMT2UxeTVybDVKYzFmZTRpb3V0czJzblJpM0tEcEtuSmRtT0Q4N1g3X0p1bjUwTFhQckx1eVZ6Q0R0MnpYR0g5ZGttSmZacVNwOVZkaGZEMi11SW4wakpxaUIzTHVhOW5PeXNoQ1JyZm1j?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics To Receive $24.5 Million Milestone From Sanofi For TZIELD Approval", "summary": "MacroGenics will receive a $24.5 million regulatory milestone payment from Sanofi after the FDA granted accelerated approval for TZIELD. This approval expands TZIELD's use for delaying the decline in endogenous insulin production in children aged eight to 17 years with recently d", "url": "https://pulse2.com/macrogenics-to-receive-24-5-million-milestone-from-sanofi-for-tzield-approval/", "source_name": "Pulse 2.0", "published_at": "2026-06-24T02:40:53", "published_display": "24 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics to Receive $24.5 Million in Regulatory Milestone Payment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/macrogenics-receive-24-5-million-205502219.html", "source_name": "MT Newswires", "published_at": "2026-06-22T20:55:02+00:00", "published_display": "22 Jun 2026 20:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD\u00ae Approval", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/macrogenics-receive-milestone-payment-sanofi-204300752.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T20:43:00+00:00", "published_display": "22 Jun 2026 20:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics stock rises on $24.5M Sanofi milestone payment", "summary": "MacroGenics Inc. (NASDAQ:MGNX) saw its shares increase after-hours due to a $24.5 million milestone payment from Sanofi. This payment followed FDA accelerated approval for TZIELD (teplizumab-mzwv) which expands its use for delaying the decline in insulin production in children wi", "url": "https://www.investing.com/news/stock-market-news/macrogenics-stock-rises-on-245m-sanofi-milestone-payment-93CH-4753948", "source_name": "Investing.com", "published_at": "2026-06-22T21:10:06", "published_display": "22 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sanofi\u2019s TZIELD approval triggers $24.5M payment to MacroGenics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOQzhzVzBwa1p0eTlGOGx3SnBYd2xtS1g2eGhtVVRxQ3VPdlVhWlIybTd6WEdVNmZLZUl3QVdYOE9pRnR2OXNqd09pVXVTd29fMHJaLVJKcm9CSzVCWndVdkJMOVo0a2VIbkxyU19uTWh6QXJzR2hzaGdTQ2YyeDU3S2lHVUtUZlhveU1ldzVpcm45SUczUERTZW56S0ZoalJxNzltWDVrd01ZV2hkQUEtT1F2ZWN1VmYzUk9Z?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The MacroGenics (MGNX) Story Is Shifting With ADC Pipeline Bets And 2026 Data Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOVTFnMmNmengxWHJpSU9VSl8tbm10RjMtUkM1c3NaakFDRkxwM0g1Nlc5elJ1TnlESUluUnBJOWxDcnVMU21hRVctN2pJaFYwbVU3MmUtV3BqTzc5cXN2RVo3dEZmOUEtYUFVdHZIcWg5UEdHLUFmYkZtWjRtQ1VrclJlR3VBUXU0M3drbUtiNzVwUGdUcGRFZV8wdWJBaXBWRzBsd05XNA?oc=5", "source_name": "Market source", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The MacroGenics (MGNX) Story Is Shifting With ADC Hopes And Execution Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQQ2Y0bFBLRzFNRjRHTVUtX0h6WWZ1SmVpZVVKZzB4TUkzZFctNHZScmJVbGt3Mm9kQ1owZmVDbTZQTnhHQjhxeEhuOEpyZFpDZkNZcEdFczNjdzEwZVFBSThua1VpTnVvSW9vajJHb1lmd0daSkdqSWJiTC1vMUs0TUlELTRLUnFaUkZuNjhHNnJibXFySHNVbGhwWWhTVXJ5WVE?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics (MGNX) Quarterly Loss Of US$36.8 Million Tests Bullish Path To Profitability", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics stock (US5562221046): $122.5M manufacturing sale to Bora marks strategic pivot", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOZk5zZ0Jid0VHVDdiVjJSRWc2Z090SHB3Rmt3Z3BtdG1hOHREdlJ4MEFGVFE4cEY1dlFtcHg5aTU5ZTA0RXloSmJLYk1QSXVfY2xrUDZ6OE1SbHJmLUNoWXlJQ3dtM1gyM1hLQ0YyeGhqanpTcm5VejJMekZNVHI2ZlJpaWwzRlg2NVNpdEZVazlGOVRTRXprNFhDR0gyZ3Nucy1wVDZrLXo1cTR3ekNLX2pkWV91YU8waU1VYTBaMWpub3FVTHo2LQ?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GMP Manufacturing Sale Gives MacroGenics Additional Non-Dilutive Capital for Pipeline Development (MGNX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOOUczZGx6SEtwRDBVSkRBLXdUVlBwTHdMWEJ5dE9TbW1pYm5qY1YyZEo3akNIcFdtQlF2bXNRTlk2el91c213dUZtMHBDSGJWZGhJcjlQZjRBMHlYV04xd3k4RGh1OG5ISGJob0JfRDBKcENZVnZWdDRPTWc2MGxNS1VJVXVIV3h6bmJZMkVMQWJ6dFNNOUtMTF92ZEhieGc3eXM2dDljamxPS3NtWkE?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics sells manufacturing operations to Bora for $122.5M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOZVJWVi1nUThnX0oxbXA1bHpNc2JqcDRCcEswLTRxcElOcUd2NDV2ZWZKbU1oMGlhZmk0c1l2MFlhRVFkMHRJRHZzMVZjSXFsaWpzbHdUR2dTOGhQYm5qMFVQUmpoOGV2cE1UVFZkS05SdXQ1MlZZZ3dyYXVGdTY1RmJQaFZkcDNfQnFfclFKUFIxR2w5LUZZdWI0X0hYT1Z0azctc1BBWlh6TFN3LUpSUkc2bG5FRUZf?oc=5", "source_name": "Investing.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics Sells GMP Manufacturing Operations to Bora Pharmaceuticals for $122.5 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNRkZ1ZHk3Y1pQUnNwdGFzTGxjOHBhRHFweElWNUhkVXdlQzJ0enk4VENHRUR4RHItc3NSc1dEX2xFUmpfNmNRd1p5azNhNW5DSmZaMGQyUnJ6NDVZQ2ktcnlRM3Joa0xYbTMyaXc3eW1YUkt0WDhyMjNrbmQwN2tYUWtKV082WWUtNFQxOFZlakVwUXhWVEtxUkpDVEh4TFFTdEVJaEpBLXFNN2dYd1ktV0JEbkhMRHRDVVM1VUpDY2ttQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will MacroGenics (MGNX) Report Negative Q1 Earnings? What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNam5yUU4yaWE5M0tkLVZ3R2JXWGFQU3BHVGtyNUhieHRUNlBncmVDVVJsTlNvdlNRazF0ZG9uV1ZOWGFGZUhWMkpXMkJNTXBtSXl5MEppVk9FZWI3QkM1N19lTFI3aldlQ3d4V29BRktDQjM4ZlB3aGZzMHVrSW11eDRCU3lHTGRnZkVzRnA1NmRQUzNPRFgza3lhUmRBamgxVHc?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ\u00ae Royalty Purchase Agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPQThSNUV6eTlzdVEycnZGcHUwVzVXVlVMOWQwaW4ySVVsQW9TX0QwbzNNOUtNNVFtRVNCZ3l2MzFhV01iWGdHS1FURENsdzFyZzEtZllhN0syWDgzaGYyeXV0SVA4dllrMjUxcTl4WmJpRGVOTGExTzlBY3E1cDRzQ3hTOFBNNEF0WngxTjZYd0NfUUZRZi1WcXpVQ3FEd0VOaXZxT3lYdGp3SlpHSHVaMzhXaw?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B. Riley Sees Upside in MacroGenics, Inc. (MGNX) Following Gilead-Driven Sector Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQTEVVU1R5Mmg0aFZhV1dDVDVkbVlKWWs2RXRlR3JpbU03elV4T1hSeFFHOWN5ejJYU1VDdTVoZFVrVDc4WERyVlNWYW5kU3hENkZTLVZJT2RMWjNCZklEd2p2NUZ2blMzazBQWW4tNmRkWS0zRXppY1dVeFB3eHdUNU1kSkpRQ2R3WlUwc1dMMXFzT3lmU05qMWFCT3NIV2lCV1E?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble (MGNX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPTFRpeEJfWVFNU0lKODBMZ3FhYnA4OWxfZmJ0bEZNWmhNLUZOVlhEdV9GQTF4QlE4OFJIUk9YT0tpWm5KUXZQY0FpZzdfU0FGaG9nbFJ0VmNCbURkTVdnc1FRUE1zcGRjc2VFUWhhdnFpdWVmZ19DN3lxRzJnWmVaLXhfeFQ2MmxTbF9ZQmRkZEZKZmZ1NTV2anNRd055cU9PZFhaVHBScV9lTGdyR2xDc0NBb3JLdTlo?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics gains removal of FDA partial hold on lead program", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxOd2JRZkZzSFpDbU14TkVPODhCdjREV3NOUUpJR2c5MjVoWG9UbTYzWDBoM0txSVF3V25QM0VUWGRLMHVDR01nNXN0YUVmQzFYb2JWWFBNM2FoMjAxTUViMnNMbVZuY0ZWSXY5T2FKckt5Q05VcUtqVGNyYkt4dlp3RHZKTzl5OVE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues Despite A 26% Share Price Rise", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MacroGenics, Inc. (NASDAQ:MGNX) is largely controlled by institutional shareholders who own 71% of the company", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQdThkeGVSMVgzTGltODNueFdGUXcyVUdVNFVIUHZhS1ZqcEJEbjJxOUxxaUVGWGN4RUlCYkZEemFmdjZSTFkzbVlaUnRlUUhxOXdLNW5wcnpnazd6QkR1Wno1aXhmUzEwUFgxelJvcUEtVGR3aWduTVZwclJpcVZJaUF5cVpRZHlf?oc=5", "source_name": "Market source", "published_at": "2025-07-11T07:00:00+00:00", "published_display": "11 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Macrogenics (MGNX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFAwQWs1bmVKRVBhVnJGOGloV3dnejJwZUtsTkNmQmNNVWEzMUpnc19KeTkzYzlnaURnZ3k3NmtOLUF3Z1VINHpnZWFZMlFIYUxwdm5N?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:24:13+00:00", "published_display": "25 Apr 2025 00:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 55, "sentiment_summary": {"positive": 14, "negative": 5, "neutral": 36, "score": 54, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 15.35, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 7.01, "count": 15}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.3, "count": 6}, {"event": "deals", "label": "Deals and strategy", "weight": 3.3, "count": 6}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 4.33, "latest_week": "2026-07-10", "one_week_move": -8.1, "four_week_move": 9.3, "twelve_week_move": 25.1, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.920045, "market_dynamics_buy_signal": false, "relative_strength": 59.746905, "fair_value_gap": -8.1, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 54.5874, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-8.1% over one week, +9.3% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "TradingView", "count": 10}, {"label": "Stock Titan", "count": 6}, {"label": "simplywall.st", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "Seeking Alpha", "count": 3}, {"label": "www.marketscreener.com", "count": 2}, {"label": "MT Newswires", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 15}, {"label": "Regulatory and legal", "count": 6}, {"label": "Deals and strategy", "count": 6}, {"label": "Balance sheet", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-8.1% over one week, +9.3% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "[144] MACROGENICS INC SEC Filing"}], "updated_at": "2026-07-17T13:48:52.864196+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}